Abstract:Background: Prostate cancer is a leading cause of cancer-related death in men worldwide. Survivin is a member of the inhibitor of apoptosis (IAP) protein family that is expressed in the majority of human tumors including prostate cancer, but is barely detectable in terminally differentiated normal cells. Downregulation of survivin could sensitize prostate cancer cells to chemotherapeutic agents in vitro and in vivo. Selenium is an essential trace element. Several studies have shown that selenium compounds inhibit the growth of prostate cancer cells. The objective of this study is to investigate whether survivin gene silencing in conjunction with selenium treatment could enhance the therapeutic efficacy for prostate cancer and to elucidate the underlying mechanisms. Methods: Expression of survivin was analyzed in a collection of normal and malignant prostatic tissues by immunohistochemical staining. In vitro studies were conducted in PC-3M, C4-2B, and 22Rv1 prostate cancer cells. The effect of selenium on survivin expression was analyzed by Western blotting and semi-quantitative RT-PCR. Survivin gene knockdown was carried out by transfecting cells with a short hairpin RNA (shRNA) designed against survivin. Cell proliferation was quantitated by the 3-(4,5-Dimethylthiazol-2-yl)- 2,5-Diphenyltetrazolium Bromide (MTT) assay and apoptosis by propidium iodide staining followed by flow cytometry analysis. Finally, in vivo tumor growth assay was performed by establishing PC-3M xenograft in nude mice and monitoring tumor growth following transfection and treatment. Results: We found that survivin was undetectable in normal prostatic tissues but was highly expressed in prostate cancers. Survivin knockdown or selenium treatment inhibited the growth of prostate cancer cells, but the selenium effect was modest. In contrast to what have been observed in other cell lines, selenium treatment had little or no effect on survivin expression in several androgen-independent prostate cancer cell lines. Survivin knockdown sensitized these cells to selenium growth inhibition and apoptosis induction. In nude mice bearing PC-3M xenografts, survivin knockdown synergizes with selenium in inhibiting tumor growth. Conclusions: Selenium could inhibit the growth of hormone-refractory prostate cancer cells both in vitro and in vivo, but the effects were modest. The growth inhibition was not mediated by downregulating survivin expression. Survivin silencing greatly enhanced the growth inhibitory effects of selenium.

Androgen Receptor Signaling Intensity Is A Key Factor In Determining The Sensitivity Of Prostate Cancer Cells To Selenium Inhibition Of Growth And Cancer-Specific Biomarkers

Monomethylated Selenium Inhibits Growth of LNCaP Human Prostate Cancer Xenograft Accompanied by a Decrease in the Expression of Androgen Receptor and Prostate-Specific Antigen (PSA)

Prostate Specific Antigen Expression is Down-Regulated by Selenium Through Disruption of Androgen Receptor Signaling.

Selenium Decreases Prostate Specific Antigen Expression by Inducing Protein Degradation and Suppressing Mrna Abundance

Methyl Selenium Metabolites Decrease Prostate-Specific Antigen Expression by Inducing Protein Degradation and Suppressing Androgen-Stimulated Transcription.

Augmented Suppression of Androgen Receptor Signaling by A Combination of Alpha-Tocopheryl Succinate and Methylseleninic Acid

Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array.

Delineation Of The Molecular Basis For Selenium-Induced Growth Arrest In Human Prostate Cancer Cells By Oligonucleotide Array

Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite.

A Proteomic Approach To Elucidate The Multiple Targets Of Selenium-Induced Cell-Growth Inhibition In Human Lung Cancer

Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells.

Methylselenocysteine preventing castration-resistant progression of prostate cancer.

Effect of Dietary Methylseleninic Acid and Se-Methylselenocysteine on Carcinogen-Induced, Androgen-Promoted Prostate Carcinogenesis in Rats

Methylseleninic Acid Provided at Nutritional Selenium Levels Inhibits Angiogenesis by Down-regulating Integrin β3 Signaling

The Suppression of Prostate LNCaP Cancer Cells Growth by Selenium Nanoparticles Through Akt/Mdm2/AR Controlled Apoptosis.

Primary Experimental Results of Methylseleninic Acid on the Proliferation Inhibition and Apoptotic Induction in Human High-Metastatic Large Cell Lung Cancer Cell Line L9981

Methylseleninic Acid Superactivates P53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse

Attenuation of Estrogen Receptor Α (erα) Signaling by Selenium in Breast Cancer Cells Via Downregulation of ERα Gene Expression

Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition

Role of GDF15 in Methylseleninic Acid-Mediated Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells

Identification of Molecular Targets Associated with Selenium-Induced Growth Inhibition in Human Breast Cells Using Cdna Microarrays.